ABSTRACT

Objective: The present study was undertaken to assess the impact of intravenous iron sucrose (Feronia IV) in the treatment of iron-deficiency anemia observed in gynecological and obstetrical practice. Methods•77 practicing gynecologists and obstetricians throughout India collaborated in the recruitment of 145 women over a period of 1 year, of which 143 were analyzable cases.

Results: The overall mean rise in hemoglobin level was observed to be 2.43 gm% at the end of 4 weeks. The dose of Iron Sucrose administered ranged from 100 mg to 1050 mg. In women who received 200 mg of the drug, the mean Hb rise was found to be 2.21 ± 1.06 gm%. Highest observable rise in hemoglobin level was 5.5 gm% with 800 mg of Iron Sucrose. No serious adverse reactions were reported during the observation period.

Conclusion: Intravenous Iron sucrose is a safe and effective treatment for the rapid reversal of iron-deficiency anemia, in obstetric and gynecological settings.